Antenatal Admissions Among Women with Opioid-Affected and Non-Opioid-Affected Deliveries

Faherty, Laura J.; Kranz, Ashley M.; Russell-Fritch, Joshua; Ruder, Teague; Patrick, Stephen W.; Stein, Bradley D.

doi:10.1007/s10995-020-02959-7

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Contrary to our expectations, there was no significant difference between receipt of postpartum SUD treatment and attendance at the postpartum visit. This lack of an association is concerning; ideally, the postpartum visit should be an opportunity to ensure appropriate linkage to SUD treatment during this vulnerable period as well as to address prevalent co-occurring mental health conditions that, consistent with other literature, 10,[36][37][38] were common in our study sample. It was also unexpected that months of Medicaid enrollment and number of prenatal visits were not associated with postpartum SUD treatment.…”

Section: Discussionsupporting

confidence: 59%

Postpartum Treatment for Substance Use Disorder Among Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Substance Exposure

Faherty

Heins

Kranz

et al. 2021

Women's Health Reports

Self Cite

View full text Add to dashboard Cite

Background: Little is known about rates of substance use disorder (SUD) treatment for women in dyads affected by substance use in the immediate postpartum period. This study's objectives were to (1) identify characteristics of mothers of infants with neonatal abstinence syndrome (NAS) and/or prenatal substance exposure (PSE) who did or did not receive SUD treatment in the first 60 days postpartum and (2) describe timing of treatment receipt. Methods: This descriptive study examined linked mother-infant dyads using Medicaid data from Louisiana, Massachusetts, and Wisconsin for 2006-2009. Dyads were included if the infant had NAS and/or PSE. Descriptive statistics on sociodemographic characteristics, prenatal SUD, mental health conditions, Medicaid enrollment, and health care utilization were reported for women who did and did not receive SUD treatment in the first 60 days postpartum. The distribution of each variable was compared using chi-square tests. The timing of first postpartum treatment in weeks since delivery was examined. Results: Among Medicaid-insured women whose infants had in utero substance exposure, 15% received any postpartum SUD treatment. Fewer than half were diagnosed with SUD prenatally. Of those who received postpartum SUD treatment, 68% had received prenatal treatment. No association was observed between postpartum SUD treatment receipt and months of Medicaid enrollment in the year before delivery, prenatal visits, or postpartum visit attendance. Conclusions: Most women who likely need postpartum SUD treatment did not receive it and multipronged solutions are needed. These findings provide a useful baseline for evaluations of policies aimed at improving maternal health.

show abstract

Section: Discussionsupporting

confidence: 59%

Postpartum Treatment for Substance Use Disorder Among Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Substance Exposure

Faherty

Heins

Kranz

et al. 2021

Women's Health Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…From 2018 to 2021, there was a significant increase in overdose deaths during pregnancy and postpartum, matching a trend of increasing overdose deaths across the US [ 1 ]. Hospitalizations throughout pregnancy are 4-fold higher for people who have an opioid-affected delivery and are frequently associated with behavioral health-related diagnoses, including substance use [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Strategies to improve delivery of equitable and evidence-informed care for pregnant and birthing people with a substance use disorder in acute care settings: A scoping review protocol

King,

Laynor,

McNeely

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

This protocol outlines a proposed scoping review to characterize evidence on implementation and quality improvement (QI) strategies that aim to improve equitable, evidence-informed care delivery for pregnant and birthing people with substance use disorder (SUD) in acute care. Untreated SUD during pregnancy is associated with an increased risk of overdose and severe maternal morbidity. Acute care settings are one important place to deliver equitable, evidence-informed clinical care. While clinical practice guidelines for substance use treatment and care of pregnant and birthing people with SUD exist, there are gaps in implementation. Our population of interest is pregnant and birthing people with SUD in an acute care setting. We will include US-based studies that describe or evaluate implementation or QI strategies, including experimental, observational, and descriptive studies published from 2016 to 2023. The proposed scoping review will be conducted in accordance with JBI methodology for scoping reviews and registered at OSF (registration number: BC4VZ). We will search MEDLINE (PubMed), CINAHL Complete (EBSCO), Scopus (Elsevier), and APA PsychInfo (Ovid) for published studies. Conference proceedings and Perinatal Quality Collaborative websites will be searched for grey literature. Two reviewers will independently screen then extract studies that meet inclusion criteria using a data extraction tool. The completion of this scoping review will help illuminate strengths and gaps in research and practice that aim to inform substance use treatment and care in acute care settings for pregnant and birthing people with SUD.

show abstract

Low barrier perinatal psychiatric care for patients with substance use disorder: meeting patients across the perinatal continuum where they are

Raffi

Gray

Conteh

et al. 2021

International Review of Psychiatry

View full text Add to dashboard Cite

Antenatal Admissions Among Women with Opioid-Affected and Non-Opioid-Affected Deliveries

Cited by 3 publications

References 30 publications

Postpartum Treatment for Substance Use Disorder Among Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Substance Exposure

Postpartum Treatment for Substance Use Disorder Among Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Substance Exposure

Strategies to improve delivery of equitable and evidence-informed care for pregnant and birthing people with a substance use disorder in acute care settings: A scoping review protocol

Low barrier perinatal psychiatric care for patients with substance use disorder: meeting patients across the perinatal continuum where they are

Contact Info

Product

Resources

About